Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average – Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.73 and traded as low as $0.72. Vaxart shares last traded at $0.74, with a volume of 1,361,347 shares changing hands.

Vaxart Price Performance

The company has a 50-day moving average of $0.66 and a two-hundred day moving average of $0.73. The company has a market capitalization of $168.72 million, a PE ratio of -1.81 and a beta of 0.62.

Hedge Funds Weigh In On Vaxart

Large investors have recently made changes to their positions in the business. Mesirow Financial Investment Management Inc. lifted its position in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 20,000 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 122,387 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after acquiring an additional 346,725 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Vaxart by 110.8% in the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.